Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Historical Acquisition Tree
Alternative names
Key: Marker Therapeutics (1) Acquired (6)
cyclophosphamide (cytoxan) (1 trial)
durvalumab (imfinzi) (1 trial)
fralpha peptide (1 trial)
fralpha vaccine (1 trial)
mt-401 (1 trial)
sargramostim (leukine) (1 trial)
tpiv200 (1 trial)
Key: Marker Therapeutics (0) Acquired (1)
her-2/neu peptide vaccine (1 trial)
Leukemia (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Trials (5 total)
Trial APIs (8 total)